Myeloid growth factors

Jeffrey Crawford, James Armitage, Lodovico Balducci, Charles Bennett, Douglas W. Blayney, Spero R. Cataland, David C. Dale, George D. Demetri, Harry P. Erba, James Foran, Alison G. Freifeld, Marti Goemann, Mark L. Heaney, Sally Htoy, Susan Hudock, Dwight D. Kloth, David J. Kuter, Gary H. Lyman, Laura Boehnke Michaud, Sarah C. MiyataMartin S. Tallman, Saroj Vadhan-Raj, Peter Westervelt, Michael K. Wong

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Neutropenia and resulting febrile neutropenia (FN) can be induced by myelosuppressive chemotherapy. FN is a major dose-limiting toxicity of chemotherapy, often requiring hospitalization to evaluate and treat. Further, these complications often result in dose reductions or treatment delays, which may compromise clinical outcomes. Although the prophylactic use of colony-stimulating factors (CSFs) can reduce the risk, severity, and duration of FN, they are not administered to all patients undergoing myelosuppressive chemotherapy because of the associated costs. Selective use, however, may enhance cost-effectiveness by directing treatment toward patients most likely to benefit. Filgrastim and pegfilgrastim, both granulocyte colony-stimulating factors (G-CSF), have FDA approval for use in the prevention of chemotherapy-induced neutropenia. In contrast, the labeled indication for sargramostim, a granulocyte-macrophage colony-stimulating factor (GM-CSF), is limited to use after induction therapy for acute myeloid leukemia and in various stem cell transplantation settings. These guidelines focus on the use of CSFs in the cancer setting; specifically addressing adult patients with solid tumors and nonmyeloid malignancies.

Original languageEnglish (US)
Pages (from-to)64-83
Number of pages20
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume7
Issue number1
DOIs
StatePublished - Jan 2009

Fingerprint

Febrile Neutropenia
Intercellular Signaling Peptides and Proteins
Colony-Stimulating Factors
Drug Therapy
Neutropenia
Neoplasms
Stem Cell Transplantation
Granulocyte Colony-Stimulating Factor
Granulocyte-Macrophage Colony-Stimulating Factor
Acute Myeloid Leukemia
Cost-Benefit Analysis
Hospitalization
Therapeutics
Guidelines
Costs and Cost Analysis

Keywords

  • Chemotherapy
  • Fever
  • Myeloid growth factors
  • NCCN clinical practice guidelines
  • Neutropenia

ASJC Scopus subject areas

  • Oncology

Cite this

Crawford, J., Armitage, J., Balducci, L., Bennett, C., Blayney, D. W., Cataland, S. R., ... Wong, M. K. (2009). Myeloid growth factors. JNCCN Journal of the National Comprehensive Cancer Network, 7(1), 64-83. https://doi.org/10.6004/jnccn.2009.0006

Myeloid growth factors. / Crawford, Jeffrey; Armitage, James; Balducci, Lodovico; Bennett, Charles; Blayney, Douglas W.; Cataland, Spero R.; Dale, David C.; Demetri, George D.; Erba, Harry P.; Foran, James; Freifeld, Alison G.; Goemann, Marti; Heaney, Mark L.; Htoy, Sally; Hudock, Susan; Kloth, Dwight D.; Kuter, David J.; Lyman, Gary H.; Michaud, Laura Boehnke; Miyata, Sarah C.; Tallman, Martin S.; Vadhan-Raj, Saroj; Westervelt, Peter; Wong, Michael K.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 7, No. 1, 01.2009, p. 64-83.

Research output: Contribution to journalArticle

Crawford, J, Armitage, J, Balducci, L, Bennett, C, Blayney, DW, Cataland, SR, Dale, DC, Demetri, GD, Erba, HP, Foran, J, Freifeld, AG, Goemann, M, Heaney, ML, Htoy, S, Hudock, S, Kloth, DD, Kuter, DJ, Lyman, GH, Michaud, LB, Miyata, SC, Tallman, MS, Vadhan-Raj, S, Westervelt, P & Wong, MK 2009, 'Myeloid growth factors', JNCCN Journal of the National Comprehensive Cancer Network, vol. 7, no. 1, pp. 64-83. https://doi.org/10.6004/jnccn.2009.0006
Crawford J, Armitage J, Balducci L, Bennett C, Blayney DW, Cataland SR et al. Myeloid growth factors. JNCCN Journal of the National Comprehensive Cancer Network. 2009 Jan;7(1):64-83. https://doi.org/10.6004/jnccn.2009.0006
Crawford, Jeffrey ; Armitage, James ; Balducci, Lodovico ; Bennett, Charles ; Blayney, Douglas W. ; Cataland, Spero R. ; Dale, David C. ; Demetri, George D. ; Erba, Harry P. ; Foran, James ; Freifeld, Alison G. ; Goemann, Marti ; Heaney, Mark L. ; Htoy, Sally ; Hudock, Susan ; Kloth, Dwight D. ; Kuter, David J. ; Lyman, Gary H. ; Michaud, Laura Boehnke ; Miyata, Sarah C. ; Tallman, Martin S. ; Vadhan-Raj, Saroj ; Westervelt, Peter ; Wong, Michael K. / Myeloid growth factors. In: JNCCN Journal of the National Comprehensive Cancer Network. 2009 ; Vol. 7, No. 1. pp. 64-83.
@article{62d2ab41f1fd43c697e16b67f30cf89f,
title = "Myeloid growth factors",
abstract = "Neutropenia and resulting febrile neutropenia (FN) can be induced by myelosuppressive chemotherapy. FN is a major dose-limiting toxicity of chemotherapy, often requiring hospitalization to evaluate and treat. Further, these complications often result in dose reductions or treatment delays, which may compromise clinical outcomes. Although the prophylactic use of colony-stimulating factors (CSFs) can reduce the risk, severity, and duration of FN, they are not administered to all patients undergoing myelosuppressive chemotherapy because of the associated costs. Selective use, however, may enhance cost-effectiveness by directing treatment toward patients most likely to benefit. Filgrastim and pegfilgrastim, both granulocyte colony-stimulating factors (G-CSF), have FDA approval for use in the prevention of chemotherapy-induced neutropenia. In contrast, the labeled indication for sargramostim, a granulocyte-macrophage colony-stimulating factor (GM-CSF), is limited to use after induction therapy for acute myeloid leukemia and in various stem cell transplantation settings. These guidelines focus on the use of CSFs in the cancer setting; specifically addressing adult patients with solid tumors and nonmyeloid malignancies.",
keywords = "Chemotherapy, Fever, Myeloid growth factors, NCCN clinical practice guidelines, Neutropenia",
author = "Jeffrey Crawford and James Armitage and Lodovico Balducci and Charles Bennett and Blayney, {Douglas W.} and Cataland, {Spero R.} and Dale, {David C.} and Demetri, {George D.} and Erba, {Harry P.} and James Foran and Freifeld, {Alison G.} and Marti Goemann and Heaney, {Mark L.} and Sally Htoy and Susan Hudock and Kloth, {Dwight D.} and Kuter, {David J.} and Lyman, {Gary H.} and Michaud, {Laura Boehnke} and Miyata, {Sarah C.} and Tallman, {Martin S.} and Saroj Vadhan-Raj and Peter Westervelt and Wong, {Michael K.}",
year = "2009",
month = "1",
doi = "10.6004/jnccn.2009.0006",
language = "English (US)",
volume = "7",
pages = "64--83",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "1",

}

TY - JOUR

T1 - Myeloid growth factors

AU - Crawford, Jeffrey

AU - Armitage, James

AU - Balducci, Lodovico

AU - Bennett, Charles

AU - Blayney, Douglas W.

AU - Cataland, Spero R.

AU - Dale, David C.

AU - Demetri, George D.

AU - Erba, Harry P.

AU - Foran, James

AU - Freifeld, Alison G.

AU - Goemann, Marti

AU - Heaney, Mark L.

AU - Htoy, Sally

AU - Hudock, Susan

AU - Kloth, Dwight D.

AU - Kuter, David J.

AU - Lyman, Gary H.

AU - Michaud, Laura Boehnke

AU - Miyata, Sarah C.

AU - Tallman, Martin S.

AU - Vadhan-Raj, Saroj

AU - Westervelt, Peter

AU - Wong, Michael K.

PY - 2009/1

Y1 - 2009/1

N2 - Neutropenia and resulting febrile neutropenia (FN) can be induced by myelosuppressive chemotherapy. FN is a major dose-limiting toxicity of chemotherapy, often requiring hospitalization to evaluate and treat. Further, these complications often result in dose reductions or treatment delays, which may compromise clinical outcomes. Although the prophylactic use of colony-stimulating factors (CSFs) can reduce the risk, severity, and duration of FN, they are not administered to all patients undergoing myelosuppressive chemotherapy because of the associated costs. Selective use, however, may enhance cost-effectiveness by directing treatment toward patients most likely to benefit. Filgrastim and pegfilgrastim, both granulocyte colony-stimulating factors (G-CSF), have FDA approval for use in the prevention of chemotherapy-induced neutropenia. In contrast, the labeled indication for sargramostim, a granulocyte-macrophage colony-stimulating factor (GM-CSF), is limited to use after induction therapy for acute myeloid leukemia and in various stem cell transplantation settings. These guidelines focus on the use of CSFs in the cancer setting; specifically addressing adult patients with solid tumors and nonmyeloid malignancies.

AB - Neutropenia and resulting febrile neutropenia (FN) can be induced by myelosuppressive chemotherapy. FN is a major dose-limiting toxicity of chemotherapy, often requiring hospitalization to evaluate and treat. Further, these complications often result in dose reductions or treatment delays, which may compromise clinical outcomes. Although the prophylactic use of colony-stimulating factors (CSFs) can reduce the risk, severity, and duration of FN, they are not administered to all patients undergoing myelosuppressive chemotherapy because of the associated costs. Selective use, however, may enhance cost-effectiveness by directing treatment toward patients most likely to benefit. Filgrastim and pegfilgrastim, both granulocyte colony-stimulating factors (G-CSF), have FDA approval for use in the prevention of chemotherapy-induced neutropenia. In contrast, the labeled indication for sargramostim, a granulocyte-macrophage colony-stimulating factor (GM-CSF), is limited to use after induction therapy for acute myeloid leukemia and in various stem cell transplantation settings. These guidelines focus on the use of CSFs in the cancer setting; specifically addressing adult patients with solid tumors and nonmyeloid malignancies.

KW - Chemotherapy

KW - Fever

KW - Myeloid growth factors

KW - NCCN clinical practice guidelines

KW - Neutropenia

UR - http://www.scopus.com/inward/record.url?scp=58149357285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149357285&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2009.0006

DO - 10.6004/jnccn.2009.0006

M3 - Article

C2 - 19176207

AN - SCOPUS:58149357285

VL - 7

SP - 64

EP - 83

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 1

ER -